Olivera Levakov
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Olivera Levakov has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Milos Nisavic
Faculty of Medicine, University of Novi Sad, Hajduk Veljkova 3, 21137 Novi Sad, Serbia
2 shared publications - Ana Segedi
University Clinical Center of Vojvodina, Clinic of Dermatovenereology, Novi Sad + University of Novi Sad, Faculty of Medicine, Novi Sad
1 shared publication - Branislava Gajic
University of Novi Sad, Faculty of Medicine, Novi Sad, Serbia + University Clinical Center of Vojvodina, Clinic for Dermatovenereology Diseases, Novi Sad, Serbia
1 shared publication David Ivanov
Department of Physiology Faculty of Medicine University of Novi Sad Novi Sad Serbia
1 shared publication- Dunja Jakovljevic
University of Novi Sad, Faculty of Pharmacy, Novi Sad, Serbia
1 shared publication - Dunja Vesković
Department of Dermatovenerology, Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia
1 shared publication
Latest Publications
- 1 January 2026
- Published by National Library of Serbia in Medicinski Pregled
- Vol. 79 (7-8) , 189-196
The role of GLP-1 agonists in the treatment of inflammatory dermatoses uloga GLP-1 agonista u terapiji inflamatornih dermatoza
Introduction. According to the latest studies, glucagon-like peptide-1 receptor agonists, in addition to reducing glycaemia and body weight, also exert strong anti-inflammatory and immunomodulatory effects and are increasingly used to treat chronic inflammatory dermatoses. Glucagon-like peptide-1 receptor agonists and psoriasis vulgaris. In practice, positive effects of glucagon-like peptide-1 receptor agonists on psoriasis severity associated with insulin resistance/diabetes mellitus type 2 and obesity have been observed. In various studies, glucagonlike peptide-1 receptor agonists resulted in significant reductions in psoriasis severity scores and improvements in quality of life. Studies have shown significant improvements in clinical picture and quality of life with glucagon-like peptide-1 receptor agonists in patients with hidradenitis suppurativa associated with obesity. Discussion. Psoriasis and hidradenitis suppurativa are dermatoses characterised by complex immune-mediated inflammatory processes. Clinical studies indicate that the use of glucagon- like peptide-1 receptor agonists leads to improvement of the clinical picture and skin changes in these patients who are obese and have type 2 diabetes/metabolic syndrome. Conclusion. Due to their metabolic, anti-inflammatory, and immunomodulatory effects, glucagon-like peptide-1 receptor agonists represent a promising therapeutic option for inflammatory dermatoses. Their effects are attributable not solely to weight loss but also to direct immunomodulatory action, which explains their efficacy independent of body weight reduction. Further randomised, placebo-controlled clinical trials are required to confirm their effectiveness.
- 1 January 2026
- Published by National Library of Serbia in Medicinski Pregled
- Vol. 79 (7-8) , 189-196
The role of GLP-1 agonists in the treatment of inflammatory dermatoses uloga GLP-1 agonista u terapiji inflamatornih dermatoza
Introduction. According to the latest studies, glucagon-like peptide-1 receptor agonists, in addition to reducing glycaemia and body weight, also exert strong anti-inflammatory and immunomodulatory effects and are increasingly used to treat chronic inflammatory dermatoses. Glucagon-like peptide-1 receptor agonists and psoriasis vulgaris. In practice, positive effects of glucagon-like peptide-1 receptor agonists on psoriasis severity associated with insulin resistance/diabetes mellitus type 2 and obesity have been observed. In various studies, glucagonlike peptide-1 receptor agonists resulted in significant reductions in psoriasis severity scores and improvements in quality of life. Studies have shown significant improvements in clinical picture and quality of life with glucagon-like peptide-1 receptor agonists in patients with hidradenitis suppurativa associated with obesity. Discussion. Psoriasis and hidradenitis suppurativa are dermatoses characterised by complex immune-mediated inflammatory processes. Clinical studies indicate that the use of glucagon- like peptide-1 receptor agonists leads to improvement of the clinical picture and skin changes in these patients who are obese and have type 2 diabetes/metabolic syndrome. Conclusion. Due to their metabolic, anti-inflammatory, and immunomodulatory effects, glucagon-like peptide-1 receptor agonists represent a promising therapeutic option for inflammatory dermatoses. Their effects are attributable not solely to weight loss but also to direct immunomodulatory action, which explains their efficacy independent of body weight reduction. Further randomised, placebo-controlled clinical trials are required to confirm their effectiveness.
- Open Access
- 1 January 2026
- Published by National Library of Serbia in Srpski arhiv za celokupno lekarstvo
- No. 00,p. 45
Atopic dermatitis - novel insights in the immunopathology of the disease
Atopic dermatitis is an inflammatory skin disease that is characterized by the chronic-relapsing course and a pronounced feeling of itching. Altered production of structural proteins, lipids and antimicrobial peptides result in the epidermal impairment leading to the early onset of disease, more severe lesions and a numerous comorbidities. Atopic dermatitis has been recently recognized as a systemic type 2 inflammation by which emerging novel therapeutic modalities reflect sophisticated molecular and immunopathological pathways. The aim of this article is to deliver thorough review of the existing knowledge regarding the most significant immunological aspects of the development and progression of atopic dermatitis.
- 1 January 2026
- Published by National Library of Serbia in Srpski arhiv za celokupno lekarstvo
- No. 00,p. 45
Open AccessAtopic dermatitis - novel insights in the immunopathology of the disease
Atopic dermatitis is an inflammatory skin disease that is characterized by the chronic-relapsing course and a pronounced feeling of itching. Altered production of structural proteins, lipids and antimicrobial peptides result in the epidermal impairment leading to the early onset of disease, more severe lesions and a numerous comorbidities. Atopic dermatitis has been recently recognized as a systemic type 2 inflammation by which emerging novel therapeutic modalities reflect sophisticated molecular and immunopathological pathways. The aim of this article is to deliver thorough review of the existing knowledge regarding the most significant immunological aspects of the development and progression of atopic dermatitis.
- Open Access
- 29 June 2025
- Published by Wiley in Skin Research and Technology
- Vol. 31 (7) , e70203
Menopause, Menstrual Cycle, and Skin Barrier Function
Background: There are a limited number of studies describing the impact of the menstrual cycle and postmenopause on the skin barrier function, and existing research data are conflicting. The aim of our research was to investigate the impact of the menstrual cycle and postmenopause on the epidermal barrier function and its main biophysical parameters—transepidermal water loss (TEWL) and skin hydration (SH).Materials and Methods: Eighty‐one female participants were included in the study, aged 18–65 years, of which 36 in the reproductive period (average age 27.06 ± 5.60 years) and 45 in postmenopause (average age 56.56 ± 4.37 years). TEWL and SH were measured during the ovulatory and mid‐luteal phases in participants in the reproductive period, and on two occasions, 7 days apart, in posmenopausal participants.Results: The mean TEWL value was significantly higher in the mid‐luteal phase (TEWL 2; 9.92 ± 1.37) compared to the ovulatory phase (TEWL 1; 8.87 ± 1.59). However, no significant difference in TEWL was observed between the two groups of participants. The mean SH value was significantly higher in the ovulatory phase (SH 1; 40.55 ± 7.80) compared to the mid‐luteal phase (SH 2; 36.27 ± 7.42). Moreover, SH in the ovulatory phase was significantly higher in comparison to the postmenopausal group (40.55:36.27; p = 0.009).Conclusion: Our study indicates a more functional epidermal barrier during the ovulatory phase, as evidenced by higher TEWL values and lower SH values compared to the mid‐luteal phase. However, the differences between the two participant groups remain intriguing, as no significant difference in TEWL was observed between them, despite significantly higher SH values in the ovulatory phase compared to the postmenopausal group.
- 29 June 2025
- Published by Wiley in Skin Research and Technology
- Vol. 31 (7) , e70203
Open AccessMenopause, Menstrual Cycle, and Skin Barrier Function
Background: There are a limited number of studies describing the impact of the menstrual cycle and postmenopause on the skin barrier function, and existing research data are conflicting. The aim of our research was to investigate the impact of the menstrual cycle and postmenopause on the epidermal barrier function and its main biophysical parameters—transepidermal water loss (TEWL) and skin hydration (SH).Materials and Methods: Eighty‐one female participants were included in the study, aged 18–65 years, of which 36 in the reproductive period (average age 27.06 ± 5.60 years) and 45 in postmenopause (average age 56.56 ± 4.37 years). TEWL and SH were measured during the ovulatory and mid‐luteal phases in participants in the reproductive period, and on two occasions, 7 days apart, in posmenopausal participants.Results: The mean TEWL value was significantly higher in the mid‐luteal phase (TEWL 2; 9.92 ± 1.37) compared to the ovulatory phase (TEWL 1; 8.87 ± 1.59). However, no significant difference in TEWL was observed between the two groups of participants. The mean SH value was significantly higher in the ovulatory phase (SH 1; 40.55 ± 7.80) compared to the mid‐luteal phase (SH 2; 36.27 ± 7.42). Moreover, SH in the ovulatory phase was significantly higher in comparison to the postmenopausal group (40.55:36.27; p = 0.009).Conclusion: Our study indicates a more functional epidermal barrier during the ovulatory phase, as evidenced by higher TEWL values and lower SH values compared to the mid‐luteal phase. However, the differences between the two participant groups remain intriguing, as no significant difference in TEWL was observed between them, despite significantly higher SH values in the ovulatory phase compared to the postmenopausal group.
- Open Access
- 1 January 2025
- Published by National Library of Serbia in Vojnosanitetski Pregled
- Vol. 82 (12) , 785-789
Correlation between clinically and histopathologically measured tumor width in basal cell carcinoma
Introduction/Aim. Basal cell carcinoma (BCC) is the most common malignant skin tumor in fair-skinned populations. Although it has low metastatic potential, it can be highly locally invasive and, in addition to impairing function, may even pose a threat to life itself. The majority of BCCs can be successfully reated by classical surgical excision with appropriate safety margins. The aim of this study was to evaluate the correlation between clinical and histopathological tumor width in excised BCCs. Methods. A prospective clinical and histopathological study included 45 subjects consecutively examined at the Department of Dermatologic Surgery and Skin Tumors, University Clinical Center of Vojvodina, Novi Sad, Serbia, with a total of 60 primary BCC specimens obtained by classical surgical excision. Medical history was recorded, and dermatological examination was performed. Prior to the excisional biopsy, an incision was made along the edge of the clinically visible tumor to the level of the papillary dermis, and the standard recommended safety margin was added. Histopathological assessment involved microscopic analysis at various magnifications. The histopathological tumor width was measured using a millimeter ocular. The total clinically estimated tumor width was determined as the distance between the two stated skin incisions, and the distance from the incision to the histopathological tumor margin was also recorded. Results. A statistically significant correlation was found between clinically determined and microscopically measured total tumor width ($P < 0.05$). The mean clinically estimated width was 9.55 ± 5.13 mm, while the histopathological width was 7.98 ± 4.75 mm. The statistically determined difference between the clinically marked and microscopically measured tumor width was less than 2.0 mm in 96.7% of cases, i.e., in 88.4% of cases, this difference in assessment was 1.0 mm or less. Conclusion. There is a positive correlation between the clinically assessed and histopathologically verified width of the BCC.
- 1 January 2025
- Published by National Library of Serbia in Vojnosanitetski Pregled
- Vol. 82 (12) , 785-789
Open AccessCorrelation between clinically and histopathologically measured tumor width in basal cell carcinoma
Introduction/Aim. Basal cell carcinoma (BCC) is the most common malignant skin tumor in fair-skinned populations. Although it has low metastatic potential, it can be highly locally invasive and, in addition to impairing function, may even pose a threat to life itself. The majority of BCCs can be successfully reated by classical surgical excision with appropriate safety margins. The aim of this study was to evaluate the correlation between clinical and histopathological tumor width in excised BCCs. Methods. A prospective clinical and histopathological study included 45 subjects consecutively examined at the Department of Dermatologic Surgery and Skin Tumors, University Clinical Center of Vojvodina, Novi Sad, Serbia, with a total of 60 primary BCC specimens obtained by classical surgical excision. Medical history was recorded, and dermatological examination was performed. Prior to the excisional biopsy, an incision was made along the edge of the clinically visible tumor to the level of the papillary dermis, and the standard recommended safety margin was added. Histopathological assessment involved microscopic analysis at various magnifications. The histopathological tumor width was measured using a millimeter ocular. The total clinically estimated tumor width was determined as the distance between the two stated skin incisions, and the distance from the incision to the histopathological tumor margin was also recorded. Results. A statistically significant correlation was found between clinically determined and microscopically measured total tumor width ($P < 0.05$). The mean clinically estimated width was 9.55 ± 5.13 mm, while the histopathological width was 7.98 ± 4.75 mm. The statistically determined difference between the clinically marked and microscopically measured tumor width was less than 2.0 mm in 96.7% of cases, i.e., in 88.4% of cases, this difference in assessment was 1.0 mm or less. Conclusion. There is a positive correlation between the clinically assessed and histopathologically verified width of the BCC.